Luciano Costa
University of Alabama at Birmingham
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Luciano Costa as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:55 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05434689 · COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomideUniversity of Alabama at Birmingham · active not recruiting · Multiple Myeloma · principal investigator
- Ph2NCT05231629 · Sequential Therapy in Multiple Myeloma Guided by MRD AssessmentsUniversity of Alabama at Birmingham · active not recruiting · Multiple Myeloma · principal investigator
- Ph1/Ph2NCT01690143 · Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell TransplantationUniversity of Alabama at Birmingham · completed · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical Protocol and Data ManagementP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · fiscal years 2020 to 2021 · $652,959 awarded in 2021Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:55 UTC. The ranking covers the 200 most relevant of 232 PubMed records, and a shared surname and initials can bring in a namesake. All 232 on PubMed
- 914 citationsRCR 26.3
- Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.N Engl J Med · 2023749 citationsRCR 61.8
- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.N Engl J Med · 2023686 citationsRCR 61.1
- Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.N Engl J Med · 2022670 citationsRCR 46.2
- 625 citationsRCR 29.5
- Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.N Engl J Med · 2019550 citationsRCR 19.6
- 311 citationsRCR 7.3
- A randomized prospective trial comparing oral sodium phosphate with standard polyethylene glycol-based lavage solution (Golytely) in the preparation of patients for colonoscopy.Am J Gastroenterol · 1990277 citationsRCR 11.0
- Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.J Natl Cancer Inst · 1994242 citationsRCR 7.1
- Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.J Clin Oncol · 2022234 citationsRCR 18.1